STAT3 and prostate carcinoma: Compared with silibinin alone, JAK1 inhibitors combined with silibinin also lead to complete reduction of STAT3 phosphorylation at Tyr705, activation of caspase, and apoptosis of prostate cancer cells (Agarwal et al., 2007).